BH.IMMUN&BIO | TYCHE INDUSTRIES | BH.IMMUN&BIO/ TYCHE INDUSTRIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -7.7 | 14.9 | - | View Chart |
P/BV | x | 1.5 | 1.8 | 82.7% | View Chart |
Dividend Yield | % | 0.0 | 1.0 | - |
BH.IMMUN&BIO TYCHE INDUSTRIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
TYCHE INDUSTRIES Mar-23 |
BH.IMMUN&BIO/ TYCHE INDUSTRIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 163 | 31.8% | |
Low | Rs | 21 | 105 | 19.5% | |
Sales per share (Unadj.) | Rs | 10.3 | 73.5 | 14.0% | |
Earnings per share (Unadj.) | Rs | -3.9 | 13.8 | -27.9% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 15.6 | -24.5% | |
Dividends per share (Unadj.) | Rs | 0 | 2.00 | 0.0% | |
Avg Dividend yield | % | 0 | 1.5 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 113.9 | 17.9% | |
Shares outstanding (eoy) | m | 43.18 | 10.25 | 421.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 1.8 | 192.2% | |
Avg P/E ratio | x | -9.4 | 9.7 | -96.9% | |
P/CF ratio (eoy) | x | -9.5 | 8.6 | -110.3% | |
Price / Book Value ratio | x | 1.8 | 1.2 | 150.5% | |
Dividend payout | % | 0 | 14.5 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 1,372 | 113.7% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 70 | 217.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 754 | 59.2% | |
Other income | Rs m | 11 | 48 | 22.0% | |
Total revenues | Rs m | 457 | 802 | 56.9% | |
Gross profit | Rs m | -161 | 160 | -100.2% | |
Depreciation | Rs m | 2 | 18 | 11.3% | |
Interest | Rs m | 71 | 0 | 706,000.0% | |
Profit before tax | Rs m | -223 | 191 | -116.7% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 49 | -114.6% | |
Profit after tax | Rs m | -166 | 142 | -117.4% | |
Gross profit margin | % | -36.0 | 21.3 | -169.4% | |
Effective tax rate | % | 25.3 | 25.7 | 98.2% | |
Net profit margin | % | -37.3 | 18.8 | -198.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 1,219 | 29.4% | |
Current liabilities | Rs m | 940 | 210 | 448.4% | |
Net working cap to sales | % | -130.6 | 133.9 | -97.5% | |
Current ratio | x | 0.4 | 5.8 | 6.5% | |
Inventory Days | Days | 85 | 13 | 679.7% | |
Debtors Days | Days | 1,135 | 1,069 | 106.2% | |
Net fixed assets | Rs m | 1,262 | 192 | 657.0% | |
Share capital | Rs m | 432 | 102 | 421.5% | |
"Free" reserves | Rs m | 450 | 1,065 | 42.3% | |
Net worth | Rs m | 882 | 1,168 | 75.6% | |
Long term debt | Rs m | 0 | 0 | - | |
Total assets | Rs m | 1,620 | 1,411 | 114.8% | |
Interest coverage | x | -2.2 | 19,085.0 | -0.0% | |
Debt to equity ratio | x | 0 | 0 | - | |
Sales to assets ratio | x | 0.3 | 0.5 | 51.5% | |
Return on assets | % | -5.9 | 10.0 | -58.9% | |
Return on equity | % | -18.9 | 12.1 | -155.4% | |
Return on capital | % | -17.2 | 16.3 | -105.5% | |
Exports to sales | % | 0 | 57.9 | 0.0% | |
Imports to sales | % | 14.5 | 19.9 | 72.7% | |
Exports (fob) | Rs m | NA | 437 | 0.0% | |
Imports (cif) | Rs m | 65 | 150 | 43.1% | |
Fx inflow | Rs m | 0 | 437 | 0.0% | |
Fx outflow | Rs m | 65 | 161 | 40.0% | |
Net fx | Rs m | -65 | 275 | -23.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 68 | 159.7% | |
From Investments | Rs m | 5 | 19 | 23.8% | |
From Financial Activity | Rs m | -147 | -15 | 957.8% | |
Net Cashflow | Rs m | -34 | 72 | -46.4% |
Indian Promoters | % | 59.3 | 62.0 | 95.6% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 0.0 | - | |
FIIs | % | 0.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 38.0 | 107.2% | |
Shareholders | 35,313 | 7,867 | 448.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES SUN PHARMA CIPLA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | TYCHE INDUSTRIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -2.23% | -1.89% | 0.31% |
1-Month | -2.23% | 15.25% | 0.08% |
1-Year | 28.97% | 13.30% | 54.11% |
3-Year CAGR | -13.27% | -0.75% | 14.46% |
5-Year CAGR | 30.36% | 25.07% | 20.04% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the TYCHE INDUSTRIES share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of TYCHE INDUSTRIES the stake stands at 62.0%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of TYCHE INDUSTRIES.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
TYCHE INDUSTRIES paid Rs 2.0, and its dividend payout ratio stood at 14.5%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of TYCHE INDUSTRIES.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on positive note, Indian share markets continued the momentum as the session progressed and ended higher.